A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.

PHASE3CompletedINTERVENTIONAL
Enrollment

3,484

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

November 30, 2014

Study Completion Date

April 30, 2015

Conditions
Influenza, Human
Interventions
BIOLOGICAL

Quadrivalent Influenza Vaccine (QIV)

One 0.5 mL intramuscular dose into the deltoid muscle

BIOLOGICAL

Trivalent Influenza Vaccine (TIV-1)

One 0.5 mL intramuscular dose into the deltoid muscle.

BIOLOGICAL

Trivalent Influenza Vaccine (TIV-2)

One 0.5 mL intramuscular dose into the deltoid muscle.

Trial Locations (33)

13901

Site 285, Binghamton

14642

Site 313, Rochester

20850

Site 291, Rockville

22911

Site 303, Charlottesville

27103

Site 305, Winston-Salem

27609

Site 306, Raleigh

28209

Site 302, Charlotte

28401

Site 309, Wilmington

29464

Site 307, Mt. Pleasant

31406

Site 292, Savannah

32207

Site 297, Jacksonville

32935

Site 293, Melbourne

35802

Site 296, Huntsville

37620

Site 308, Bristol

37760

Site 311, Jefferson City

37912

Site 312, Knoxville

37938

Site 304, Knoxville

46545

Site 295, Mishawaka

61614

Site 294, Peoria

63141

Site 287, St Louis

67207

Site 317, Witchita

68005

Site 316, Bellevue

73112

Site 299, Oklahoma City

76135

Site 282, Forth Worth

76904

Site 288, San Angelo

78705

Site 283, Austin

83642

Site 289, Meridian

84124

Site 300, Salt Lake City

89104

Site 298, Las Vegas

90036

Site 286, Los Angeles

92108

Site 315, San Diego

06460

Site 301, Milford

01844

Site 310, Methuen

All Listed Sponsors
lead

Seqirus

INDUSTRY

NCT02214225 - A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above. | Biotech Hunter | Biotech Hunter